<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887458</url>
  </required_header>
  <id_info>
    <org_study_id>J0932</org_study_id>
    <secondary_id>JHMI-IRB number: NA_00027099</secondary_id>
    <nct_id>NCT00887458</nct_id>
  </id_info>
  <brief_title>A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy</brief_title>
  <official_title>A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to test an investigational drug, called itraconazole, in the
      treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration
      (FDA) for the treatment of various fungal infections such as fingernail/toenail infections
      and other more serious fungal infections. The word &quot;investigational&quot; means that itraconazole
      is not approved for use in people with cancer. However, the FDA is allowing the use of
      itraconazole in this research study. Itraconazole has been shown to have activity against
      cancer (including prostate cancer) in the laboratory, but has not been tested against cancer
      in humans.

      The purpose of this study is to find out:

        -  If itraconazole is safe when given at two different doses

        -  How itraconazole affects prostate specific antigen (PSA): a blood test that measures
           substances released by prostate cancer

        -  Whether itraconazole can delay further prostate cancer growth and spread

        -  How itraconazole affects other markers of prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Itraconazole is an oral, generic, and commercially available antifungal drug with a long
      safety record when used at doses ranging from 200 to 600 mg daily.

      Itraconazole has been shown in cellular and animal models to be a potent angiogenesis
      inhibitor as well as a Hedgehog pathway antagonist; both pathways are considered important in
      prostate cancer. Itraconazole has not previously been tested as an antineoplastic agent, but
      given its well-established safety profile, the gap between further preclinical studies and
      human clinical trials can be narrowed to accelerate development of this agent as a putative
      anticancer drug. The investigators hypothesize that itraconazole will prevent PSA progression
      in a significant proportion of men with metastatic CRPC and that it will have an acceptable
      safety profile at both doses. Itraconazole may ultimately delay the need for chemotherapy in
      these men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy With One of Two Dose-levels of Itraconazole: 200 mg or 600 mg Daily.</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy. &quot;PSA progression&quot; is defined as a 25% increase in PSA over baseline [or nadir (lowest)] and an increase in absolute PSA level by at least 2 ng/mL, both confirmed by a second value at least 4 weeks later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Proportion of Men With ≥ 50% PSA Reduction From Baseline.</measure>
    <time_frame>Baseline and approximately 2 years from open enrollment</time_frame>
    <description>Will be reported as the percentage of men with ≥ 50% PSA reduction from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 200 mg</intervention_name>
    <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 300mg</intervention_name>
    <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed prostate adenocarcinoma.

          -  Presence of distant metastases on bone scan, CT scan, or MRI scan.

          -  Progression after androgen deprivation (and anti-androgen withdrawal).

          -  Rising serum PSA (Prostate Cancer Working Group (PCWG2) definition).

          -  Castrate levels of serum testosterone (i.e., ≤ 50 ng/dL).

          -  Age &gt; 18 years.

          -  ECOG performance status score ≤ 2, and/or Karnofsky score ≥ 50%.

          -  Life expectancy &gt; 6 months.

          -  Adequate kidney, liver, and bone marrow function.

          -  Willingness to sign informed consent and adhere to study requirements.

        Exclusion Criteria:

          -  Recent surgery, radiation therapy, combined androgen blockade, or investigational
             therapies in the last 8 weeks.

          -  Previous chemotherapy for metastatic prostate cancer.

          -  Concomitant use of second-line hormonal agents (e.g., ketoconazole, DES)

          -  Current use of corticosteroids, except if on a stable dose for ≥ 3 months.

          -  History of malabsorption syndrome (may affect itraconazole absorption).

          -  Allergic reactions to itraconazole or similar compounds.

          -  Concurrent use of drugs that interact with the CYP3A4 system (caution only).

          -  Presence of known brain metastases.

          -  Prior malignancy in the last 3 years, with some exceptions.

          -  Uncontrolled major infectious, cardiac, or pulmonary illnesses.

          -  Prolonged corrected QT interval (&gt; 450 msec) on electrocardiography.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Carducci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <results_first_submitted>December 11, 2013</results_first_submitted>
  <results_first_submitted_qc>December 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2014</results_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic prostate cancer</keyword>
  <keyword>castration resistant prostate cancer</keyword>
  <keyword>rising PSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Itraconazole 200 mg: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
        </group>
        <group group_id="P2">
          <title>High Dose</title>
          <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Itraconazole 300mg: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Itraconazole 200 mg: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
        </group>
        <group group_id="B2">
          <title>High Dose</title>
          <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Itraconazole 300mg: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="60" upper_limit="81"/>
                    <measurement group_id="B2" value="71" lower_limit="52" upper_limit="89"/>
                    <measurement group_id="B3" value="73" lower_limit="52" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy With One of Two Dose-levels of Itraconazole: 200 mg or 600 mg Daily.</title>
        <description>To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy. &quot;PSA progression&quot; is defined as a 25% increase in PSA over baseline [or nadir (lowest)] and an increase in absolute PSA level by at least 2 ng/mL, both confirmed by a second value at least 4 weeks later.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>Based on how many participants were evaluable for the study primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Itraconazole</title>
            <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Itraconazole 200 mg: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>High Dose Itraconazole</title>
            <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Itraconazole 300mg: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy With One of Two Dose-levels of Itraconazole: 200 mg or 600 mg Daily.</title>
          <description>To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy. &quot;PSA progression&quot; is defined as a 25% increase in PSA over baseline [or nadir (lowest)] and an increase in absolute PSA level by at least 2 ng/mL, both confirmed by a second value at least 4 weeks later.</description>
          <population>Based on how many participants were evaluable for the study primary endpoint</population>
          <units>percent of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="1.5" upper_limit="36.4"/>
                    <measurement group_id="O2" value="48" lower_limit="27.8" upper_limit="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Proportion of Men With ≥ 50% PSA Reduction From Baseline.</title>
        <description>Will be reported as the percentage of men with ≥ 50% PSA reduction from baseline.</description>
        <time_frame>Baseline and approximately 2 years from open enrollment</time_frame>
        <population>One subject in the high dose arm was not evaluable on account of subject discontinuing study drug during cycle 1 due to clinical progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Itraconazole 200 mg: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>High Dose</title>
            <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Itraconazole 300mg: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Proportion of Men With ≥ 50% PSA Reduction From Baseline.</title>
          <description>Will be reported as the percentage of men with ≥ 50% PSA reduction from baseline.</description>
          <population>One subject in the high dose arm was not evaluable on account of subject discontinuing study drug during cycle 1 due to clinical progression.</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="19.5"/>
                    <measurement group_id="O2" value="14.3" lower_limit="4.0" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose</title>
          <description>Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Itraconazole 200 mg: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)</description>
        </group>
        <group group_id="E2">
          <title>High Dose</title>
          <description>Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Itraconazole 300mg: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Carducci</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-614-3977</phone>
      <email>carducci@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

